by Paul McIntosh | Oct 5, 2021 | 2021, Press Releases
Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...
by Paul McIntosh | Sep 23, 2021 | 2021, Press Releases
This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...
by Paul McIntosh | Aug 25, 2021 | 2021, Press Releases
Aberdeen, August 24, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O’Neil, Ph.D., Chief Executive Officer of NovaBiotics, delivered...
by Paul McIntosh | Aug 2, 2021 | 2021, Press Releases
Highlights proprietary peptide platform and immune-based approach with manifold therapeutic advantages over traditional drug classes to combat life-threatening fungal and bacterial infectious diseases Aberdeen, August 2, 2021. NovaBiotics Ltd, a privately held...
by Paul McIntosh | Jul 7, 2021 | 2021, Press Releases
NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland’s “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland’s Top Ten...
by Paul McIntosh | Jun 21, 2021 | 2021, Press Releases
Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias Aberdeen, June 21, 2021. NovaBiotics Ltd, a privately held clinical stage company...
Contact Us
News and Events
Technology
Recent Comments